photo-teva
Photo: Teva
29 September 2015Asia-Pacific

Global Pharma IP Forum: Japan’s Supreme Court Teva decision a ‘death sentence’

A Japanese lawyer has described a ruling by the Supreme Court of Japan as a “death sentence” for product-by-process patents and said it is a good time for drugs companies to challenge rivals’ patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
23 February 2023   New recruit joins from DLA Piper and will head up firm’s litigation team | Previously worked on Pfizer v Samsung Bioepis, Jusand v Rattlejack & Murray Engineering, and Pfizer v Sandoz | Follows prosecutor Chris Vindurampulle who joined in October last year.
Asia-Pacific
24 May 2022   The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.
Asia-Pacific
30 November 2020   The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.